Chemours EPS CC
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$2.00
- Latest quarter, Q2 FY26
- −$1.81
- Fiscal year 2025
- −$2.56
- −669% on the year before
Chemours' earnings per share was −$2.00 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.81.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.56 | −669% |
| FY2024 | $0.45 | n/a |
| FY2023 | −$1.60 | −145% |
| FY2022 | $3.56 | −2% |
| FY2021 | $3.63 | +173% |
| FY2020 | $1.33 | n/a |
| FY2019 | −$0.36 | −107% |
| FY2018 | $5.43 | +39% |
| FY2017 | $3.90 | +12900% |
| FY2016 | $0.03 | n/a |
| FY2015 | −$0.50 | n/a |
| FY2014 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.81 | n/a | −$2.00 | |
| Q1 FY26 | −$0.19 | n/a | −$2.72 | |
| Q4 FY25 | −$0.31 | n/a | −$2.56 | |
| Q3 FY25 | $0.31 | n/a | −$2.33 | |
| Q2 FY25 | −$2.53 | −749% | −$2.86 | |
| Q1 FY25 | −$0.03 | −108% | $0.06 | |
| Q4 FY24 | −$0.08 | n/a | $0.45 | |
| Q3 FY24 | −$0.22 | −375% | $0.41 | |
| Q2 FY24 | $0.39 | n/a | $0.71 | |
| Q1 FY24 | $0.36 | −63% | −$2.20 | |
| Q4 FY23 | −$0.12 | n/a | −$1.60 | |
| Q3 FY23 | $0.08 | −95% | −$2.13 |
Against its peers
Companies in Chemicals nearest Chemours' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CCChemours | −$2.00 | |
| ROGRogers | $1.75 | |
| NGVTIngevity | $1.47 | |
| IOSPInnospec | $4.90 | +545% a year |
| FULFuller H B | $3.59 | +72% a year |
| WDFCWD 40 | $6.58 | +4% a year |
| CRONCronos | $0.20 | +300% a year |
| AVNTAvient | $1.85 | +43% a year |
| CBTCabot | $3.54 | −54% a year |
| FTKFlotek Industries | $0.99 | +125% a year |
| CSWCSW Industrials | $7.29 | −13% a year |
| Peer median | $2.69 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Chemours
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.